Is the regulation by miRNAs of NTPDase1 and ecto-5’-nucleotidase genes involved with the different profiles of breast cancer subtypes?
Breast cancer (BC) is a public health problem worldwide, causing suffering and premature death among women. As a heterogeneous disease, BC-specific diagnosis and treatment are challenging. Ectonucleotidases are related to tumor development and their expression may vary among BC. miRNAs may participa...
Saved in:
Published in: | Purinergic signalling Vol. 18; no. 1; pp. 123 - 133 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Dordrecht
Springer Netherlands
01-03-2022
Springer Nature B.V |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Breast cancer (BC) is a public health problem worldwide, causing suffering and premature death among women. As a heterogeneous disease, BC-specific diagnosis and treatment are challenging. Ectonucleotidases are related to tumor development and their expression may vary among BC. miRNAs may participate in epigenetic events and may regulate ectonucleotidases in BC. This study aimed to evaluate the expression of ectonucleotidases according to BC subtypes and to predict if there is post-transcriptional regulation of them by miRNAs. MCF 10A (non-tumorigenic), MCF7 (luminal BC), and MDA-MB-231 (triple-negative BC - TNBC) breast cell lines were used and
ENTPD1
(the gene encoding for NTPDase1) and
NT5E
(the gene encoding for ecto-5’-nucleotidase) gene expression was determined. Interestingly, the expression of
ENTPD1
was only observed in MCF7 and
NT5E
was lower in MCF7 compared to MDA-MB-231 cell line. ATP, ADP, and AMP hydrolysis were observed on the surface of all cell lines, being higher in MDA-MB-231. Like qPCR, the activity of AMP hydrolysis was also lower in the MCF7 cells, which may represent a striking feature of this BC subtype. In silico analyses confirmed that the miRNAs miR-101-3p, miR-141-3p, and miR-340-5p were higher expressed in MCF7 cells and targeted
NT5E
mRNA. Altogether, data suggest that the regulation of
NT5E
by miRNAs in MCF7 lineage may direct the molecular profile of luminal BC. Thus, we suggest that the roles of ecto-5’-nucleotidase and the aforementioned miRNAs must be unraveled in TNBC to be possibly defined as diagnostic and therapeutic targets. |
---|---|
AbstractList | Breast cancer (BC) is a public health problem worldwide, causing suffering and premature death among women. As a heterogeneous disease, BC-specific diagnosis and treatment are challenging. Ectonucleotidases are related to tumor development and their expression may vary among BC. miRNAs may participate in epigenetic events and may regulate ectonucleotidases in BC. This study aimed to evaluate the expression of ectonucleotidases according to BC subtypes and to predict if there is post-transcriptional regulation of them by miRNAs. MCF 10A (non-tumorigenic), MCF7 (luminal BC), and MDA-MB-231 (triple-negative BC - TNBC) breast cell lines were used and
ENTPD1
(the gene encoding for NTPDase1) and
NT5E
(the gene encoding for ecto-5’-nucleotidase) gene expression was determined. Interestingly, the expression of
ENTPD1
was only observed in MCF7 and
NT5E
was lower in MCF7 compared to MDA-MB-231 cell line. ATP, ADP, and AMP hydrolysis were observed on the surface of all cell lines, being higher in MDA-MB-231. Like qPCR, the activity of AMP hydrolysis was also lower in the MCF7 cells, which may represent a striking feature of this BC subtype. In silico analyses confirmed that the miRNAs miR-101-3p, miR-141-3p, and miR-340-5p were higher expressed in MCF7 cells and targeted
NT5E
mRNA. Altogether, data suggest that the regulation of
NT5E
by miRNAs in MCF7 lineage may direct the molecular profile of luminal BC. Thus, we suggest that the roles of ecto-5’-nucleotidase and the aforementioned miRNAs must be unraveled in TNBC to be possibly defined as diagnostic and therapeutic targets. Breast cancer (BC) is a public health problem worldwide, causing suffering and premature death among women. As a heterogeneous disease, BC-specific diagnosis and treatment are challenging. Ectonucleotidases are related to tumor development and their expression may vary among BC. miRNAs may participate in epigenetic events and may regulate ectonucleotidases in BC. This study aimed to evaluate the expression of ectonucleotidases according to BC subtypes and to predict if there is post-transcriptional regulation of them by miRNAs. MCF 10A (non-tumorigenic), MCF7 (luminal BC), and MDA-MB-231 (triple-negative BC - TNBC) breast cell lines were used and ENTPD1 (the gene encoding for NTPDase1) and NT5E (the gene encoding for ecto-5'-nucleotidase) gene expression was determined. Interestingly, the expression of ENTPD1 was only observed in MCF7 and NT5E was lower in MCF7 compared to MDA-MB-231 cell line. ATP, ADP, and AMP hydrolysis were observed on the surface of all cell lines, being higher in MDA-MB-231. Like qPCR, the activity of AMP hydrolysis was also lower in the MCF7 cells, which may represent a striking feature of this BC subtype. In silico analyses confirmed that the miRNAs miR-101-3p, miR-141-3p, and miR-340-5p were higher expressed in MCF7 cells and targeted NT5E mRNA. Altogether, data suggest that the regulation of NT5E by miRNAs in MCF7 lineage may direct the molecular profile of luminal BC. Thus, we suggest that the roles of ecto-5'-nucleotidase and the aforementioned miRNAs must be unraveled in TNBC to be possibly defined as diagnostic and therapeutic targets. |
Author | de Melo Neto, Angelo Borges de Sousa Cardoso, Thaís Cunha de Araújo, Thaise Gonçalves Martins, Christina Aparecida da Silva, Fernanda Cardoso de Souza Gomes, Matheus Fürstenau, Cristina Ribas |
Author_xml | – sequence: 1 givenname: Fernanda Cardoso surname: da Silva fullname: da Silva, Fernanda Cardoso organization: Laboratory of Animal Cell Culture, Institute of Biotechnology (IBTEC), Federal University of Uberlândia – sequence: 2 givenname: Angelo Borges surname: de Melo Neto fullname: de Melo Neto, Angelo Borges organization: Laboratory of Bioinformatics and Molecular Analysis, Institute of Biotechnology (IBTEC), Federal University of Uberlândia – sequence: 3 givenname: Christina Aparecida surname: Martins fullname: Martins, Christina Aparecida organization: Laboratory of Animal Cell Culture, Institute of Biotechnology (IBTEC), Federal University of Uberlândia – sequence: 4 givenname: Thaís Cunha surname: de Sousa Cardoso fullname: de Sousa Cardoso, Thaís Cunha organization: Laboratory of Bioinformatics and Molecular Analysis, Institute of Biotechnology (IBTEC), Federal University of Uberlândia – sequence: 5 givenname: Matheus surname: de Souza Gomes fullname: de Souza Gomes, Matheus organization: Laboratory of Bioinformatics and Molecular Analysis, Institute of Biotechnology (IBTEC), Federal University of Uberlândia – sequence: 6 givenname: Thaise Gonçalves surname: de Araújo fullname: de Araújo, Thaise Gonçalves organization: Laboratory of Genetics and Biotechnology, Institute of Biotechnology (IBTEC), Federal University of Uberlândia – sequence: 7 givenname: Cristina Ribas surname: Fürstenau fullname: Fürstenau, Cristina Ribas email: c.furstenau@ufabc.edu.br organization: Laboratory of Vascular Biochemistry, Center for Natural and Human Sciences (CCNH), Federal University of ABC |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34741235$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1uEzEUhS3UiraBF2CBLLFhM9S_87MBVeWvUlUQKmvLM75OXE3sYHuCsmPJK_B6PAkmaVNgwca2dL57fI_OCTrwwQNCTyh5QQlpThOlnLCKMFqRrmWiEg_QMZUNrzop6oP9m7dH6CSlG0KkYLx7iI64aARlXB6j7xcJ5wXgCPNp1NkFj_sNXrpPV2cJB4uvrj--1gko1t5gGHKo5M9vPyo_DSOE7EzR8Bw8JOz8OoxrMPiry4utp3HWQgSf8SoG60bYOvYRdMp40H6AiNPU580K0qtH6NDqMcHj23uGPr99c33-vrr88O7i_OyyGsrOueJC9ByYprouZ0ug1VKbpuQilgpiORhJtTED0LY2ujdSmsYS3ggCA-mAz9DLne9q6pdQOJ-jHtUquqWOGxW0U38r3i3UPKxV20oiuroYPL81iOHLBCmrpUsDjKP2EKakmOwE60Td8II--we9CVP0JZ5idWFI2xRshtiOGmJIKYLdL0OJ-l202hWtStFqW7QSZejpnzH2I3fNFoDvgFQkP4d4__d_bH8Bfx64kQ |
CitedBy_id | crossref_primary_10_1007_s11302_022_09840_y crossref_primary_10_1002_cbin_12202 crossref_primary_10_1016_j_jinorgbio_2024_112524 |
Cites_doi | 10.1016/j.bcp.2021.114406 10.1007/s13277-015-4513-9 10.1007/s11010-006-9148-0 10.1016/j.mcna.2020.08.003 10.1016/j.lungcan.2015.10.005 10.1038/onc.2016.206 10.1007/s13277-015-3683-9 10.3322/caac.21492 10.1002/jgm.3230 10.1093/hmg/ddt044 10.1155/2012/959848 10.3390/ijms19123837 10.1007/s11302-020-09760-9 10.1002/cncr.25860 10.2147/ott.s326178 10.1002/jcb.28416 10.18632/oncotarget.23703 10.1016/j.critrevonc.2020.103196 10.1016/j.canlet.2011.08.018 10.3892/ol.2017.6439 10.3892/or.2015.3972 10.18632/oncotarget.5067 10.3892/or.2015.4411 10.1016/j.gene.2016.11.037 10.1186/s12943-017-0582-2 10.1186/s12885-017-3250-4 10.1007/s11302-014-9423-6 10.7717/peerj.3551 10.3892/ijmm.2016.2679 10.7150/ijbs.12777 10.1002/ijc.31937 10.1158/0008-5472.can-12-0420 10.1073/pnas.1222251110 10.1007/s11010-021-04199-x 10.1016/j.jconrel.2021.07.021 10.1002/mnfr.201600994 10.3389/fphar.2017.00661 10.1038/s41598-021-85379-z 10.1007/s11302-021-09785-8 10.4236/ijcm.2017.82006 10.3892/ijmm.2016.2557 10.7150/ijbs.51123 10.1006/abio.1976.9999 10.3389/fonc.2020.526850 10.1007/s13402-020-00558-w 10.1093/neuonc/not067 10.1016/0003-2697(86)90640-8 10.3892/or.2020.7724 10.11606/D.87.2014.tde-08052014-163253 10.3390/ijms21228589 10.1016/j.yjmcc.2016.02.010 10.1007/s11010-011-1025-9 10.3892/or.2020.7699 10.26355/eurrev_201910_19291 10.1038/s41598-017-10863-4 10.3109/10428194.2014.907893 10.2147/ott.s264600 10.7150/jca.19315 10.1097/md.0000000000004989 10.3390/cells9112496 10.1155/2014/123010 10.1159/000363010 10.3389/fgene.2021.682503 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to Springer Nature B.V. 2021 2021. The Author(s), under exclusive licence to Springer Nature B.V. The Author(s), under exclusive licence to Springer Nature B.V. 2021. |
Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature B.V. 2021 – notice: 2021. The Author(s), under exclusive licence to Springer Nature B.V. – notice: The Author(s), under exclusive licence to Springer Nature B.V. 2021. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1007/s11302-021-09824-4 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Public Health |
EISSN | 1573-9546 |
EndPage | 133 |
ExternalDocumentID | 10_1007_s11302_021_09824_4 34741235 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico grantid: 446747/2014-9 funderid: http://dx.doi.org/10.13039/501100003593 – fundername: ; grantid: 446747/2014-9 |
GroupedDBID | --- -56 -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 1N0 203 29P 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2WC 2~H 30V 4.4 406 408 409 40D 40E 53G 5VS 67N 67Z 6NX 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAFGU AAHNG AAIAL AAJKR AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABWNU ABXPI ACBMV ACBRV ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACSNA ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFGCZ AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG AOIJS ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BAWUL BDATZ BGNMA CAG COF CS3 CSCUP DDRTE DIK DNIVK DPUIP DU5 E3Z EBLON EBS EIOEI EJD EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GX1 GXS HF~ HG5 HG6 HLICF HMJXF HQYDN HRMNR HVGLF HYE HZ~ I09 IHE IJ- IKXTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAK LLZTM M4Y MA- N2Q NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM OK1 P2P PF0 PT4 QOR QOS R89 R9I RIG ROL RPM RPX RSV S16 S1Z S27 S3A S3B SAP SBL SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZN T13 TR2 TSG TSK TSV TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U ZMTXR ZOVNA ~A9 AACDK AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c474t-344b3e2a1a6e2a80e8a5ad74230f140f3ed51addce186dabd55d7f03740ec09e3 |
IEDL.DBID | RPM |
ISSN | 1573-9538 |
IngestDate | Tue Sep 17 21:17:59 EDT 2024 Thu Oct 24 22:42:59 EDT 2024 Wed Nov 13 11:34:30 EST 2024 Thu Nov 21 21:07:09 EST 2024 Wed Oct 16 00:40:31 EDT 2024 Sat Dec 16 12:08:28 EST 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | CD73 Adenosine Breast cancer miR-141-3p miR-101-3p miR340-5p |
Language | English |
License | 2021. The Author(s), under exclusive licence to Springer Nature B.V. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c474t-344b3e2a1a6e2a80e8a5ad74230f140f3ed51addce186dabd55d7f03740ec09e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850496 |
PMID | 34741235 |
PQID | 2629408767 |
PQPubID | 2043646 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850496 proquest_miscellaneous_2594294673 proquest_journals_2629408767 crossref_primary_10_1007_s11302_021_09824_4 pubmed_primary_34741235 springer_journals_10_1007_s11302_021_09824_4 |
PublicationCentury | 2000 |
PublicationDate | 2022-03-01 |
PublicationDateYYYYMMDD | 2022-03-01 |
PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Dordrecht |
PublicationPlace_xml | – name: Dordrecht – name: Netherlands |
PublicationSubtitle | The Official Journal of the International Purine Club |
PublicationTitle | Purinergic signalling |
PublicationTitleAbbrev | Purinergic Signalling |
PublicationTitleAlternate | Purinergic Signal |
PublicationYear | 2022 |
Publisher | Springer Netherlands Springer Nature B.V |
Publisher_xml | – name: Springer Netherlands – name: Springer Nature B.V |
References | Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA (2018) Targeting adenosine receptor signaling in cancer immunotherapy. Int J Mol Sci 19(12):3837. https://doi.org/10.3390/ijms19123837 Mohammadi-YeganehSParyanMArefianEVaseiMGhanbarianHMahdianRMicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathwayTumour Biol2016377899390001:CAS:528:DC%2BC28Xht1Kmtr4%3D10.1007/s13277-015-4513-926758430 YangFLuoLJZhangLWangDDYangSJDingLMiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxelGene.20176002181:CAS:528:DC%2BC28XhvFylt7fE10.1016/j.gene.2016.11.03727913185 CaiXYWangXFLiJDongJNLiuJQLiNPOverexpression of CD39 and high tumoral CD39+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancerInt J Clin Exp Pathol20158111475764268238014713587 ArivazhaganRLeeJBayarsaikhanDKwakPSonMByunKMicroRNA-340 inhibits the proliferation and promotes the apoptosis of colon cancer cells by modulating REV3LOncotarget20189451556810.18632/oncotarget.2370329435169 JiangZGWuYCsizmadiaEFeldbrüggeLEnjyojiKTiggesJCharacterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasmaPurinergic Signal201410461181:CAS:528:DC%2BC2cXhsVers7rF10.1007/s11302-014-9423-6251650064272360 ShiZLiYQianXHuYLiuJZhangSMiR-340 inhibits triple-negative breast cancer progression by reversing EZH2 mediated miRNAs dysregulated expressionsJ Cancer20178153037481:CAS:528:DC%2BC1cXitlWku73K10.7150/jca.19315289288955604455 BurnstockGPurinergic signalling: therapeutic developmentsFront Pharmacol2017866110.3389/fphar.2017.00661 StaggJBeavisPADivisekeraULiuMCMöllerADarcyPKCD73-deficient mice are resistant to carcinogenesisCancer Res2012729219061:CAS:528:DC%2BC38Xmt1ymsLY%3D10.1158/0008-5472.can-12-042022396496 YiJHuangWZWenYQYiYCEffect of miR-101 on proliferation and oxidative stress-induced apoptosis of breast cancer cells via Nrf2 signaling pathwayEur Rev Med Pharmacol Sci20192320893191:STN:280:DC%2BB3MjmtFarsg%3D%3D10.26355/eurrev_201910_1929131696480 BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalAGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin201868639442410.3322/caac.214923020759330207593 GuanHDaiZMaYWangZLiuXWangXMicroRNA-101 inhibits cell proliferation and induces apoptosis by targeting EYA1 in breast cancerInt J Mol Med20163761643511:CAS:528:DC%2BC2sXivV2jtr8%3D10.3892/ijmm.2016.255727082308 ZongaroSHukemaRD’AntoniSDavidovicLBarbryPCataniaMVThe 3′ UTR of FMR1 mRNA is a target of miR-101, miR-129-5p and miR-221: implications for the molecular pathology of FXTAS at the synapseHum Mol Genet201322101971821:CAS:528:DC%2BC3sXms1GgsLY%3D10.1093/hmg/ddt04423390134 NiXWanWMaJLiuXZhengBHeZA novel prognostic biomarker of luminal breast cancer: high CD39 expression is related to poor survivalFront Genet2021126825031:CAS:528:DC%2BB3MXhvVOjurjI10.3389/fgene.2021.682503342209578250154 BooLHoWYAliNMYeapSKKyHChanKGMiRNA transcriptome profiling of spheroid-enriched cells with cancer stem cell properties in human breast MCF-7 cell lineInt J Biol Sci2016124427451:CAS:528:DC%2BC28Xht1Oqsb7J10.7150/ijbs.12777270196274807162 NovitskayaTChepurkoECovarrubiasRNovitskiySRyzhovSVFeoktistovIExtracellular nucleotide regulation and signaling in cardiac fibrosisJ Mol Cell Cardiol20169347561:CAS:528:DC%2BC28XjsFKnsbw%3D10.1016/j.yjmcc.2016.02.010 WangLLiLGuoRLiXLuYGuanXmiR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2Cell Physiol Biochem2014342413221:CAS:528:DC%2BC2cXhtl2rtbfE10.1159/00036301025059472 LoiSPommeySHaibe-KainsBBeavisPADarcyPKSmythMJCD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancerProc Natl Acad Sci U S A20131102711091610.1073/pnas.1222251110237762413704029 VolovatSRVolovatCHordilaIHordilaDAMiresteanCCMironOTMiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a reviewFront Oncol20201052685010.3389/fonc.2020.526850333300197716774 PetrukNTuominenSÅkerfeltMMattssonJSandholmJNeesMCD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancerSci Rep202111160351:CAS:528:DC%2BB3MXmvVOntb0%3D10.1038/s41598-021-85379-z337275917966763 XuSShaoQQSunJTYangNXieQWangDHSynergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomasNeuro-oncology20131591160721:CAS:528:DC%2BC3sXhtlGnu7zJ10.1093/neuonc/not067237374883748917 YangXPeiSWangHJinYYuFZhouBTiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73BMC Cancer20171712551:CAS:528:DC%2BC1cXitVSns7jP10.1186/s12885-017-3250-4283999155387263 WuZSWuQWangCQWangXNHuangJZhaoJJmiR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-MetCancer2011117132842521:CAS:528:DC%2BC3MXns1Klur0%3D10.1002/cncr.2586021692045 LiuJPangYWangHLiYSunXXuFmiR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3aXi bao yu fen zi mian yi xue za zhi201632329930326927545 ChenCPSunZLLuXWuWXGuoWLLuJJMiR-340 suppresses cell migration and invasion by targeting MYO10 in breast cancerOncol Rep2016352709161:CAS:528:DC%2BC2sXpvFOntg%3D%3D10.3892/or.2015.441126573744 SabitHCevikETombulogluHAbdel-GhanySTombulogluGEstellerMTriple negative breast cancer in the era of miRNACrit Rev Oncol Hematol202115710319610.1016/j.critrevonc.2020.10319633307198 MakCSYungMMHuiLMLeungLLLiangRChenKMicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axisMol Cancer2017161111:CAS:528:DC%2BC1cXjt1Cit7c%3D10.1186/s12943-017-0582-2280958645240442 Del Carmen Martínez-Jiménez V, Méndez-Mancilla A, Patricia Portales-Pérez D (2018) miRNAs in nutrition, obesity, and cancer: the biology of miRNAs in metabolic disorders and its relationship with cancer development. Mol Nutr Food Res 62(1) https://doi.org/10.1002/mnfr.201600994 AbousamraNKSalah El-DinMHamza ElzahafEEsmaelMEEctonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemiaLeuk Lymphoma201556111391:CAS:528:DC%2BC2MXit1Cntbs%3D10.3109/10428194.2014.90789324684231 Liu S, Li D, Liu J, Wang H, Horecny I, Shen R et al (2021) A novel CD73 inhibitor SHR170008 suppresses adenosine in tumor and enhances anti-tumor activity with PD-1 blockade in a mouse model of breast cancer. Onco Targets Ther 14:4561–4574. https://doi.org/10.2147/ott.s326178 Gheler FV, Cappellari AR, Renck D, de Souza JB, de Melo RO, Moehlecke BZ et al (2021) AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments. Mol Cell Biochem 476(10):3719–3727. https://doi.org/10.1007/s11010-021-04199-x JinFQiJLiuDYouYShuGDuYCancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancerJ Control Release2021337901041:CAS:528:DC%2BB3MXhsF2gtL7K10.1016/j.jconrel.2021.07.02134274385 Moulatlet ACB (2013) MicroRNAs como biomarcadores no carcinoma papilífero de tireóide: associação com mutações somáticas frequentes e significado biológico. Universidade de São Paulo, p 125. https://doi.org/10.11606/D.87.2014.tde-08052014-163253 Sun S, Ma J, Xie P, Wu Z, Tian X (2020) Hypoxia-responsive miR-141-3p is involved in the progression of breast cancer via mediating the HMGB1/HIF-1α signaling pathway. J Gene Med 22(10):e3230. https://doi.org/10.1002/jgm.3230 INCA INdC. Estatísticas de câncer. 2021. https://www.inca.gov.br/numeros-de-cancer EunSYKoYSParkSWChangKCKimHJP2Y2 nucleotide receptor-mediated extracellular signal-regulated kinases and protein kinase C activation induces the invasion of highly metastatic breast cancer cellsOncol Rep20153411952021:CAS:528:DC%2BC2sXovVSrsg%3D%3D10.3892/or.2015.397226063340 Reyna-Jeldes M, Díaz-Muñoz M (2021) Autocrine and paracrine purinergic signaling in the most lethal types of cancer. Purinergic Signal 17(3):345–370. https://doi.org/10.1007/s11302-021-09785-8 ZhangBChengBLiFSDingJHFengYYZhuoGZHigh expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinomaTumour Biol20153612941191:CAS:528:DC%2BC2MXhtV2ltrzM10.1007/s13277-015-3683-926113408 ChanKMDelfertDJungerKDA direct colorimetric assay for Ca2+ -stimulated ATPase activityAnal Biochem19861572375801:CAS:528:DyaL28XlvVKgtL0%3D10.1016/0003-2697(86)90640-82946250 BraccoPABertoniAPWinkMRNTPDase5/PCPH as a new target in highly aggressive tumors: a systematic reviewBioMed Res Int201420141230101:CAS:528:DC%2BC2cXhs1GitbnP10.1155/2014/123010250456564090452 HEALTH P. Breast cancer treatment. 2019. https://www.cancer.gov/types/breast/hp/breast-treatment-pdq BooLHoWYMohd AliNYeapSKKyHChanKGPhenotypic and microRNA transcriptomic profiling of the MDA-MB-231 spheroid-enriched CSCs with comparison of MCF-7 microRNA profiling datasetPeerJ201751:CAS:528:DC%2BC1cXitlKrurjI10.7717/peerj.3551287175965511503 CaiXYNiXCYiYHeHWWangJXFuYPOverexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resectionMedicine201695401:CAS:528:DC%2BC28XhslSis7fP10.1097/md.0000000000004989277495555059057 LiJTJiaLTLiuNNZhuXSLiuQQWangXLMiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7Oncotarget.2015631308183010.18632/oncotarget.5067263607804741570 NarayanAKLeeCILehmanCDScreening for breast cancerMed Clin N Am2020104610072110.1016/j.mcna.2020.08.00333099447 TamajusukuASCarrillo-SepúlvedaMABraganholEWinkMRSarkisJJBarreto-ChavesMLActivity and expression of ecto-5'-nucleotidase/CD73 are increased by thyroid hormones in vascular smooth muscle cellsMol Cell Biochem20062891–265721:CAS:528:DC%2BD28XptVajtbo%3D10.1007/s11010-006-9148-016718378 Han G, Qiu N, Luo K, Liang H, Li H (2019) Downregulation of miroRNA-141 mediates acquired resistance to trastuzumab and is asso 9824_CR43 Z Huang (9824_CR55) 2021; 17 9824_CR44 X Yang (9824_CR41) 2017; 17 J Liu (9824_CR50) 2016; 32 9824_CR42 Y Yu (9824_CR58) 2020; 44 S Loi (9824_CR18) 2013; 110 TT Manavalan (9824_CR54) 2011; 313 AK Narayan (9824_CR4) 2020; 104 S Schmid (9824_CR36) 2015; 90 T Novitskaya (9824_CR10) 2016; 93 LS Bergamin (9824_CR12) 2012; 2012 L Boo (9824_CR64) 2016; 12 F Bray (9824_CR27) 2018; 68 PA Bracco (9824_CR16) 2014; 2014 J Stagg (9824_CR17) 2012; 72 R Arivazhagan (9824_CR69) 2018; 9 9824_CR51 9824_CR52 9824_CR53 F Yang (9824_CR21) 2017; 600 B Zhang (9824_CR34) 2015; 36 SY Eun (9824_CR31) 2015; 34 S Xu (9824_CR38) 2013; 15 S Mohammadi-Yeganeh (9824_CR62) 2016; 37 Z Shi (9824_CR61) 2017; 8 SR Volovat (9824_CR22) 2020; 10 KM Chan (9824_CR25) 1986; 157 ZS Wu (9824_CR57) 2011; 117 9824_CR14 X Ni (9824_CR37) 2021; 12 9824_CR65 ZG Jiang (9824_CR11) 2014; 10 LT Woods (9824_CR9) 2021; 187 9824_CR20 H Sabit (9824_CR23) 2021; 157 H Jiang (9824_CR48) 2020; 13 XY Cai (9824_CR32) 2016; 95 F Jin (9824_CR19) 2021; 337 MM Bradford (9824_CR26) 1976; 72 G Burnstock (9824_CR7) 2017; 8 F Di Virgilio (9824_CR40) 2017; 36 9824_CR8 L Wang (9824_CR47) 2014; 34 C Song (9824_CR68) 2017; 08 9824_CR6 9824_CR5 S Zongaro (9824_CR66) 2013; 22 L Boo (9824_CR63) 2017; 5 CP Chen (9824_CR56) 2016; 35 9824_CR29 XY Cai (9824_CR33) 2015; 8 H Guan (9824_CR45) 2016; 37 9824_CR2 9824_CR1 9824_CR28 JT Li (9824_CR49) 2015; 6 NK Abousamra (9824_CR35) 2015; 56 J Yi (9824_CR46) 2019; 23 J Ferlay (9824_CR3) 2019; 144 R Bao (9824_CR13) 2016; 38 AR Cappellari (9824_CR39) 2012; 359 L Meng (9824_CR59) 2020; 44 AS Tamajusuku (9824_CR24) 2006; 289 9824_CR30 N Petruk (9824_CR15) 2021; 11 N Maskey (9824_CR60) 2017; 14 CS Mak (9824_CR67) 2017; 16 |
References_xml | – volume: 187 start-page: 114406 year: 2021 ident: 9824_CR9 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2021.114406 contributor: fullname: LT Woods – volume: 37 start-page: 8993 issue: 7 year: 2016 ident: 9824_CR62 publication-title: Tumour Biol doi: 10.1007/s13277-015-4513-9 contributor: fullname: S Mohammadi-Yeganeh – volume: 289 start-page: 65 issue: 1–2 year: 2006 ident: 9824_CR24 publication-title: Mol Cell Biochem doi: 10.1007/s11010-006-9148-0 contributor: fullname: AS Tamajusuku – volume: 104 start-page: 1007 issue: 6 year: 2020 ident: 9824_CR4 publication-title: Med Clin N Am doi: 10.1016/j.mcna.2020.08.003 contributor: fullname: AK Narayan – volume: 90 start-page: 516 issue: 3 year: 2015 ident: 9824_CR36 publication-title: Lung Cancer (Amsterdam, Netherlands). doi: 10.1016/j.lungcan.2015.10.005 contributor: fullname: S Schmid – volume: 36 start-page: 293 issue: 3 year: 2017 ident: 9824_CR40 publication-title: Oncogene doi: 10.1038/onc.2016.206 contributor: fullname: F Di Virgilio – volume: 36 start-page: 9411 issue: 12 year: 2015 ident: 9824_CR34 publication-title: Tumour Biol doi: 10.1007/s13277-015-3683-9 contributor: fullname: B Zhang – volume: 68 start-page: 394 issue: 6 year: 2018 ident: 9824_CR27 publication-title: CA Cancer J Clin doi: 10.3322/caac.21492 contributor: fullname: F Bray – ident: 9824_CR52 doi: 10.1002/jgm.3230 – volume: 22 start-page: 1971 issue: 10 year: 2013 ident: 9824_CR66 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddt044 contributor: fullname: S Zongaro – volume: 2012 start-page: 959848 year: 2012 ident: 9824_CR12 publication-title: J Biomed Biotechnol doi: 10.1155/2012/959848 contributor: fullname: LS Bergamin – ident: 9824_CR6 doi: 10.3390/ijms19123837 – ident: 9824_CR14 doi: 10.1007/s11302-020-09760-9 – volume: 117 start-page: 2842 issue: 13 year: 2011 ident: 9824_CR57 publication-title: Cancer doi: 10.1002/cncr.25860 contributor: fullname: ZS Wu – ident: 9824_CR42 doi: 10.2147/ott.s326178 – ident: 9824_CR53 doi: 10.1002/jcb.28416 – volume: 9 start-page: 5155 issue: 4 year: 2018 ident: 9824_CR69 publication-title: Oncotarget doi: 10.18632/oncotarget.23703 contributor: fullname: R Arivazhagan – volume: 157 start-page: 103196 year: 2021 ident: 9824_CR23 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2020.103196 contributor: fullname: H Sabit – volume: 313 start-page: 26 issue: 1 year: 2011 ident: 9824_CR54 publication-title: Cancer Lett doi: 10.1016/j.canlet.2011.08.018 contributor: fullname: TT Manavalan – volume: 14 start-page: 2261 issue: 2 year: 2017 ident: 9824_CR60 publication-title: Oncol Lett doi: 10.3892/ol.2017.6439 contributor: fullname: N Maskey – volume: 34 start-page: 195 issue: 1 year: 2015 ident: 9824_CR31 publication-title: Oncol Rep doi: 10.3892/or.2015.3972 contributor: fullname: SY Eun – volume: 6 start-page: 30818 issue: 31 year: 2015 ident: 9824_CR49 publication-title: Oncotarget. doi: 10.18632/oncotarget.5067 contributor: fullname: JT Li – volume: 35 start-page: 709 issue: 2 year: 2016 ident: 9824_CR56 publication-title: Oncol Rep doi: 10.3892/or.2015.4411 contributor: fullname: CP Chen – ident: 9824_CR28 – volume: 600 start-page: 21 year: 2017 ident: 9824_CR21 publication-title: Gene. doi: 10.1016/j.gene.2016.11.037 contributor: fullname: F Yang – volume: 16 start-page: 11 issue: 1 year: 2017 ident: 9824_CR67 publication-title: Mol Cancer doi: 10.1186/s12943-017-0582-2 contributor: fullname: CS Mak – volume: 17 start-page: 255 issue: 1 year: 2017 ident: 9824_CR41 publication-title: BMC Cancer doi: 10.1186/s12885-017-3250-4 contributor: fullname: X Yang – volume: 10 start-page: 611 issue: 4 year: 2014 ident: 9824_CR11 publication-title: Purinergic Signal doi: 10.1007/s11302-014-9423-6 contributor: fullname: ZG Jiang – volume: 5 year: 2017 ident: 9824_CR63 publication-title: PeerJ doi: 10.7717/peerj.3551 contributor: fullname: L Boo – volume: 38 start-page: 969 issue: 3 year: 2016 ident: 9824_CR13 publication-title: Int J Mol Med doi: 10.3892/ijmm.2016.2679 contributor: fullname: R Bao – volume: 32 start-page: 299 issue: 3 year: 2016 ident: 9824_CR50 publication-title: Xi bao yu fen zi mian yi xue za zhi contributor: fullname: J Liu – volume: 12 start-page: 427 issue: 4 year: 2016 ident: 9824_CR64 publication-title: Int J Biol Sci doi: 10.7150/ijbs.12777 contributor: fullname: L Boo – ident: 9824_CR2 – volume: 144 start-page: 1941 issue: 8 year: 2019 ident: 9824_CR3 publication-title: Int J Cancer doi: 10.1002/ijc.31937 contributor: fullname: J Ferlay – volume: 72 start-page: 2190 issue: 9 year: 2012 ident: 9824_CR17 publication-title: Cancer Res doi: 10.1158/0008-5472.can-12-0420 contributor: fullname: J Stagg – volume: 110 start-page: 11091 issue: 27 year: 2013 ident: 9824_CR18 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1222251110 contributor: fullname: S Loi – ident: 9824_CR44 doi: 10.1007/s11010-021-04199-x – volume: 337 start-page: 90 year: 2021 ident: 9824_CR19 publication-title: J Control Release doi: 10.1016/j.jconrel.2021.07.021 contributor: fullname: F Jin – ident: 9824_CR30 doi: 10.1002/mnfr.201600994 – volume: 8 start-page: 661 year: 2017 ident: 9824_CR7 publication-title: Front Pharmacol doi: 10.3389/fphar.2017.00661 contributor: fullname: G Burnstock – volume: 11 start-page: 6035 issue: 1 year: 2021 ident: 9824_CR15 publication-title: Sci Rep doi: 10.1038/s41598-021-85379-z contributor: fullname: N Petruk – ident: 9824_CR29 – ident: 9824_CR5 doi: 10.1007/s11302-021-09785-8 – volume: 08 start-page: 55 year: 2017 ident: 9824_CR68 publication-title: Int J Clin Med doi: 10.4236/ijcm.2017.82006 contributor: fullname: C Song – volume: 37 start-page: 1643 issue: 6 year: 2016 ident: 9824_CR45 publication-title: Int J Mol Med doi: 10.3892/ijmm.2016.2557 contributor: fullname: H Guan – volume: 17 start-page: 236 issue: 1 year: 2021 ident: 9824_CR55 publication-title: Int J Biol Sci doi: 10.7150/ijbs.51123 contributor: fullname: Z Huang – volume: 72 start-page: 248 year: 1976 ident: 9824_CR26 publication-title: Anal Biochem doi: 10.1006/abio.1976.9999 contributor: fullname: MM Bradford – volume: 10 start-page: 526850 year: 2020 ident: 9824_CR22 publication-title: Front Oncol doi: 10.3389/fonc.2020.526850 contributor: fullname: SR Volovat – ident: 9824_CR43 doi: 10.1007/s13402-020-00558-w – volume: 15 start-page: 1160 issue: 9 year: 2013 ident: 9824_CR38 publication-title: Neuro-oncology doi: 10.1093/neuonc/not067 contributor: fullname: S Xu – volume: 157 start-page: 375 issue: 2 year: 1986 ident: 9824_CR25 publication-title: Anal Biochem doi: 10.1016/0003-2697(86)90640-8 contributor: fullname: KM Chan – volume: 44 start-page: 1662 issue: 4 year: 2020 ident: 9824_CR59 publication-title: Oncol Rep doi: 10.3892/or.2020.7724 contributor: fullname: L Meng – ident: 9824_CR20 doi: 10.11606/D.87.2014.tde-08052014-163253 – ident: 9824_CR51 doi: 10.3390/ijms21228589 – volume: 8 start-page: 14757 issue: 11 year: 2015 ident: 9824_CR33 publication-title: Int J Clin Exp Pathol contributor: fullname: XY Cai – volume: 93 start-page: 47 year: 2016 ident: 9824_CR10 publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2016.02.010 contributor: fullname: T Novitskaya – volume: 359 start-page: 315 issue: 1–2 year: 2012 ident: 9824_CR39 publication-title: Mol Cell Biochem doi: 10.1007/s11010-011-1025-9 contributor: fullname: AR Cappellari – ident: 9824_CR1 – volume: 44 start-page: 1511 issue: 4 year: 2020 ident: 9824_CR58 publication-title: Oncol Rep doi: 10.3892/or.2020.7699 contributor: fullname: Y Yu – volume: 23 start-page: 8931 issue: 20 year: 2019 ident: 9824_CR46 publication-title: Eur Rev Med Pharmacol Sci doi: 10.26355/eurrev_201910_19291 contributor: fullname: J Yi – ident: 9824_CR65 doi: 10.1038/s41598-017-10863-4 – volume: 56 start-page: 113 issue: 1 year: 2015 ident: 9824_CR35 publication-title: Leuk Lymphoma doi: 10.3109/10428194.2014.907893 contributor: fullname: NK Abousamra – volume: 13 start-page: 9599 year: 2020 ident: 9824_CR48 publication-title: OncoTargets Ther doi: 10.2147/ott.s264600 contributor: fullname: H Jiang – volume: 8 start-page: 3037 issue: 15 year: 2017 ident: 9824_CR61 publication-title: J Cancer doi: 10.7150/jca.19315 contributor: fullname: Z Shi – volume: 95 issue: 40 year: 2016 ident: 9824_CR32 publication-title: Medicine doi: 10.1097/md.0000000000004989 contributor: fullname: XY Cai – ident: 9824_CR8 doi: 10.3390/cells9112496 – volume: 2014 start-page: 123010 year: 2014 ident: 9824_CR16 publication-title: BioMed Res Int doi: 10.1155/2014/123010 contributor: fullname: PA Bracco – volume: 34 start-page: 413 issue: 2 year: 2014 ident: 9824_CR47 publication-title: Cell Physiol Biochem doi: 10.1159/000363010 contributor: fullname: L Wang – volume: 12 start-page: 682503 year: 2021 ident: 9824_CR37 publication-title: Front Genet doi: 10.3389/fgene.2021.682503 contributor: fullname: X Ni |
SSID | ssj0054239 |
Score | 2.3528988 |
Snippet | Breast cancer (BC) is a public health problem worldwide, causing suffering and premature death among women. As a heterogeneous disease, BC-specific diagnosis... |
SourceID | pubmedcentral proquest crossref pubmed springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 123 |
SubjectTerms | 5'-Nucleotidase - genetics 5'-Nucleotidase - metabolism Antigens, CD Apyrase Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - genetics Breast Neoplasms - pathology Cancer Research CD39 antigen Cell Line, Tumor Epigenetics Female Gene expression Gene Expression Regulation, Neoplastic - genetics Gene regulation Human Physiology Humans Hydrolysis MicroRNAs - genetics Neurosciences Nucleotidase Original Original Article Pharmacology/Toxicology Post-transcription Public health Therapeutic targets Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - pathology Tumors |
SummonAdditionalLinks | – databaseName: SpringerLINK Complete - EKUAL dbid: AEJHL link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7R9sKFV3mkLchIiAsY5WEnzgmt6FYFoRWCInGLHNuBFaoXbbKVeuuRv9C_11_CjDfZ1VI4wGUvHjlrezwznsc3AM-sLGqrEkNdAxxHKel4LWPNc2ekMaVJ0zg0sf1UTL6owzHB5GQr14X__mqISAZBva51oxAbp4yCuFSp4GILdlD3SGTundH43fH7QQBLwrQLMKlFRtFJ1dfK_HmWTX10zci8niv5W8A06KGj2_-1gjtwqzc72WjJJ3fhhvP3YHfk8cl9es6es5AIGjzsu_DzbcvQLGTzZZt6PDhWn7PT6cfJqGWzhk1OPhyi7kuY9paR05_Lq4tL7gkZedZNLY6xryRC2dSj8DtzlpG3N8w59GPpWN8sPMxYU2Z8xwxx4Jy1i5ocw-3r-_D5aHzy5pj3DRu4EYXoeCZEnblUJzrHXxU7paW2FAuOG3zINZmzMkGBalyicqtrK6UtGkLAiZ2JS5c9gG0_8-4RsFjVAh9bjSxzIwzS1mibNbEu0XxKktxG8GI4turHEpejWiMw00ZXuNFV2OhKRHAwnGzV39G2SvO0FITIV0TwdDWMt4tCJtq72QJpZIkKG5VJFsHDJSOsPpfhmqnSOIJig0VWBITcvTnip98CgrdSEl9meQQvB05Z_62_r2Lv38j34WZKtRohYe4Atrv5wj2GrdYunvQ35heq7xKY priority: 102 providerName: Springer Nature |
Title | Is the regulation by miRNAs of NTPDase1 and ecto-5’-nucleotidase genes involved with the different profiles of breast cancer subtypes? |
URI | https://link.springer.com/article/10.1007/s11302-021-09824-4 https://www.ncbi.nlm.nih.gov/pubmed/34741235 https://www.proquest.com/docview/2629408767 https://search.proquest.com/docview/2594294673 https://pubmed.ncbi.nlm.nih.gov/PMC8850496 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6x5cIFAeURWiojIS7gbl5OnBNatVsVBKsKisQtih8pkVhvtdmt1BtH_gJ_j1_CjJNsKRUXLrnYspPMeGY8j28AXhiRKyMjTV0DLEcpabkSYcUzq4XWhY7j0Dex_ZTPvsjDKcHkiKEWxifta9Xsu2_zfdd89bmV53M9HvLExicfDqQUaNhm4xGM0DYcruid-BWEaOdBUvOEYpOyr5Tp6uUoTMcpKyEsZJxy6sqTpKhUY9_u7Q_FdMPavJk0-Vfk1Cuko3twt7ck2aR74_twy7oHsD1xeIueX7KXzOd2eqf5Nvx42zK09Niy6zyPtGDqks2bj7NJyxY1m52eHKI6i1jlDCM_Phe_vv_kjsCOF6vG4Bg7I6nIGofy7MIaRg5cv-bQYmXF-v7ffkVFye4rpomplqxdK_L1tm8ewuej6enBMe97MHCN_2XFkzRViY2rqMrwKUMrK1EZCu-GNd7N6sQaEaGM1DaSmamUEcLkNYHahFaHhU0ewZZbOPsEWChVivenWhSZTjXOVWhu1WFVoEUURZkJ4NVAgPK8g9oor0CViXIlUq70lCvTAHYHGpX9sWvLOIuLlED28gCeb4bxwFAUpHJ2scY5okAdjPohCeBxR9LNdgMvBJBfI_ZmAoFxXx9BHvWg3D1PBvB6YIur1_r3Vzz974124E5MlRg-HW4XtlbLtX0Go9as9-D2ZPru-P2ePxe_ARsEEME |
link.rule.ids | 230,315,729,782,786,887,27933,27934,41073,42142,48344,48347,49649,49652,52153,53800,53802 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB7R9gCXFijQQAEjIS5gyUnsxDmhFe3SFWWFYJG4RYnt0D00W22ySL31yCvwejwJM95kV0vhAJe9eOSs7fHMeH6-AXhuVVpaHRrqGuA4SknHSyUKnjijjMlMFAnfxPZTOv6ij44JJkf2tTA-270PSXpJvS52oxgbp5QCkelIcrkFOzJLJPLyzmA0eTvsJbAiUDuPk5rGFJ7UXbHMn2fZVEjXrMzryZK_RUy9Ihru_d8SbsNuZ3iywZJT7sANV9-F_UGNj-7zS_aC-VRQ72Pfh--jhqFhyObLRvV4dKy8ZOfTj-NBw2YVG08-HKH2C1lRW0Zuf65-Xv3gNWEjz9qpxTH2lYQom9Yo_r45y8jf6-fsO7K0rGsX7mcsKTe-ZYZ4cM6aRUmu4eb1Pfg8PJ68OeFdywZuZCpbHktZxi4qwiLBXy2cLlRhKRosKnzKVbGzKkSRalyoE1uUVimbVoSBI5wRmYvvw3Y9q90BMKFLic-tSmWJkQZpS7TOKlFkaECFYWIDeNmfW36xRObI1xjMtNE5bnTuNzqXARz2R5t3t7TJoyTKJGHypQE8Ww3j_aKgSVG72QJpVIYqG9VJHMCDJSesPhfjmqnWOIB0g0dWBITdvTlST888hrfWCt9mSQCvek5Z_62_r-Lhv5E_hZsnk_en-elo_O4R3IqocsOnzx3CdjtfuMew1djFk-76_AIVGBaI |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbhMxEB7RVkJcKFAoCwWMhLiA1f2xd70nFJFELVRRBUXittq1vZBDnSq7QeqtR16B1-NJmHF2E4XCAXHJxSNvbI_nxzPzDcALI7PKqEhT1wDLUUpaXsmw5KnVUutcx3Hom9h-zCaf1XBEMDmrKn6f7d6HJJc1DYTS5NrDC1MfrgvfKN7GKb0gzFUsuNiCHYGeDHL6zmD07uikl8aSAO48ZmqWUKhSdYUzf55lUzldszivJ07-Fj31Smm8-__LuQO3O4OUDZYcdBduWHcP9gYOnfHzS_aS-RRR__a-B9-PG4YGI5svG9jjkbLqkp1PP0wGDZvVbHJ2OkStGLHSGUbhAC5_Xv3gjjCTZ-3U4Bj7QsKVTR2KxW_WMHoH9nP2nVpa1rUR9zNWlDPfMk28OWfNoqIn4-bNffg0Hp29PeJdKweuRSZanghRJTYuozLFXxVaVcrSUJQ4rNHFqxNrZISiVttIpaasjJQmqwkbJ7Q6zG3yALbdzNmHwEJVCXTDapmnWmikrdBqq8MyR8MqilITwKv-DIuLJWJHscZmpo0ucKMLv9GFCOCgP-aiu71NEadxLgirLwvg-WoY7x0FU0pnZwukkTmqclQzSQD7S65YfS7BNVMNcgDZBr-sCAjTe3PETb96bG-lJPpsaQCve65Z_62_r-LRv5E_g5unw3Fxcjx5_xhuxVTQ4bPqDmC7nS_sE9hqzOJpd5N-AW8EH0s |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+the+regulation+by+miRNAs+of+NTPDase1+and+ecto-5%E2%80%99-nucleotidase+genes+involved+with+the+different+profiles+of+breast+cancer+subtypes%3F&rft.jtitle=Purinergic+signalling&rft.au=da+Silva%2C+Fernanda+Cardoso&rft.au=de+Melo+Neto%2C+Angelo+Borges&rft.au=Martins%2C+Christina+Aparecida&rft.au=de+Sousa+Cardoso%2C+Tha%C3%ADs+Cunha&rft.date=2022-03-01&rft.pub=Springer+Netherlands&rft.issn=1573-9538&rft.eissn=1573-9546&rft.volume=18&rft.issue=1&rft.spage=123&rft.epage=133&rft_id=info:doi/10.1007%2Fs11302-021-09824-4&rft.externalDocID=10_1007_s11302_021_09824_4 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1573-9538&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1573-9538&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1573-9538&client=summon |